diprotin a has been researched along with Myocardial Infarction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashraf, A; Ashraf, M; Dai, B; Huang, W; Millard, RW; Wang, Y; Zhang, D; Zhao, T | 1 |
| Assmann, G; Brunner, S; Fischer, R; Franz, WM; Gröbner, M; Hacker, M; Huber, B; Krieg, L; Mueller-Hoecker, J; Rischpler, C; Theiss, HD; Vallaster, M; Vanchev, Y; Wollenweber, T; Zaruba, MM | 1 |
2 other study(ies) available for diprotin a and Myocardial Infarction
| Article | Year |
|---|---|
Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts.
Topics: Adenoviridae; Animals; Chemokine CXCL12; Combined Modality Therapy; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Models, Animal; Myocardial Infarction; Neovascularization, Physiologic; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Ventricular Function, Left | 2010 |
Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Topics: Animals; Antigens, CD34; Benzylamines; Chemokine CXCL12; Cyclams; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Heart Function Tests; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Leukocyte Common Antigens; Mice; Models, Biological; Myocardial Infarction; Neovascularization, Physiologic; Oligopeptides; Perfusion; Proto-Oncogene Proteins c-kit; Receptors, CXCR4; Stem Cell Transplantation; Survival Analysis | 2011 |